Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 60

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 60
---
 not completed, any of these risks may materialize and may adversely affect Enfusion’s businesses, financial condition, financial results and stock price. Clearwater expects to obtain financing in connection with the Transactions and cannot guarantee that it will be able to obtain such financing on favorable terms or at all. Clearwater anticipates that the funds needed to complete the Transactions will be derived from a combination of (i) available cash on hand and (ii) third-party debt financing. Clearwater’s ability to obtain any such new debt financing will depend on, among other factors, prevailing market conditions and other factors beyond Clearwater’s control. Clearwater cannot assure you that it will be able to obtain new debt financing on terms acceptable to it or at all, and any such failure could materially adversely affect its operations and financial condition. Clearwater’s obligation to complete the Transactions is not conditioned upon the receipt of any financing. The unaudited pro forma condensed combined financial information included in this Proxy Statement/Prospectus is preliminary and the actual financial condition and results of operations after the Transactions may differ materially from them. The unaudited pro forma condensed combined financial information included in this Proxy Statement/Prospectus is presented for illustrative purposes only and is not necessarily indicative of what Clearwater’s actual financial condition or results of operations would have been had the Transactions been completed on the dates indicated. The unaudited pro forma condensed combined financial information reflects adjustments, which are based upon assumptions, preliminary estimates and accounting reclassifications, to record Enfusion’s identifiable assets acquired and liabilities assumed at fair value and the resulting goodwill recognized. The purchase price allocation reflected in this Proxy Statement/Prospectus is preliminary, and final allocation of the purchase price will be based upon the actual purchase price and the fair value of the assets and liabilities of Enfusion as of the date of the completion of the Transactions. Accordingly, the final accounting adjustments as a result of the 34

acquisition may differ materially from the pro forma adjustments reflected in this Proxy Statement/Prospectus. For more information, see the section titled “Unaudited Pro Forma Condensed
Combined Financial Information.”

Completion of the Transactions may trigger change in control provisions in certain agreements to which Enfusion is a party.

The completion of the Transactions may trigger change in control provisions in certain agreements to which
Enfusion is a party. If Enfusion and Clearwater are unable to negotiate waivers of those provisions, the counterparties may exercise their rights and remedies under the agreements, potentially terminating the agreements or seeking monetary damages